ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021

27 Jul 2021 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

12 Jul 2021 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma

30 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology

04 Jun 2021 08:00:01 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

20 May 2021 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

19 May 2021 15:51:33 By Nasdaq GlobeNewswire

Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021

12 May 2021 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2021 Financial Results 

05 May 2021 15:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

28 Apr 2021 08:24:16 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter Financial Results on May 5, 2021

27 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma

21 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

19 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

12 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting

10 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

25 Feb 2021 15:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

18 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences

09 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational Medicine

26 Jan 2021 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

05 Jan 2021 07:30:00 By Nasdaq GlobeNewswire